Q&A - Stem cells could offer treatment for a myriad of diseases

Tuesday, January 28, 2014

Q.What are stem cells?

Stem cells are different however as they are at an earlier stage in cell development and this means they can make more cells and transform into different cell types such as a skin stem cell can make all the different types of skin cells.

Q. And there are two types? A.Yes. There are two types of stem cells: embryonic stem cells and adult stem cells. Embryonic stem cells can generate all cells of the human body. Adult stem calls generate a more limited number of human cell types.

Q.Why are stem cells so important? A.For many years, adult stem cells have been used to treat rare blood and certain cancers.

However, adult stem cells cant generate all cell types. For example, scientists say there doesnt appear to be an adult stem cell that can make insulin- secreting cells of the pancreas. Embryonic stem cells can, however, as they can generate all cell types and the aim of scientists is to use these embryonic cells to generate healthy tissue to replace cells compromised by disease. This means that embryonic cells are more scientifically useful.

Q. And its also embryonic cells that are the more controversial, right? A.The use of embryonic stem cells is controversial here and in other countries as certain groups believe it is morally wrong to experiment on an embryo that could become a human. Embryonic stem cells are taken from embryos left over after assisted fertility treatments. According to the Irish Stem Cell Foundation, if they werent used for research into human disease, they would be discarded as medical waste. Embryos are not created purely for research purposes they say.

Q. Why are they so useful? A. Among the conditions which scientists believe may eventually be treated by stem cell therapy are Parkinsons disease, Alzheimers disease, heart disease, stroke, arthritis, diabetes, burns and spinal cord damage. Early trials are under way for treating forms of blindness. It is also hoped we can learn from embryonic stem cells how early body tissues develops and more about the pathway of diseases. This will enable us to make better and more effective drugs.

Irish Examiner Ltd. All rights reserved

Link:
Q&A - Stem cells could offer treatment for a myriad of diseases

Recommendation and review posted by Bethany Smith

Published Monday, 27 January 2014

A young teenager with diabetes tests his blood levels. (UTV)

Scientists behind the new facility at the National University of Ireland Galway will aim to produce adult cells to combat conditions like diabetes, arthritis and heart disease.

Stem cells created at the lab will be used in clinical trials following regulatory approval - the first of which is to test their effects on critical limb ischemia, a common complication associated with diabetes which often results in amputation.

The cells, mesenchymal stem cells (MSCs), will undergo safety tests after being isolated from bone marrow from donors and grown in the laboratory to generate sufficient quantities.

The university said it will position it as a global player in regenerative medicine.

NUI Galway's Centre for Cell Manufacturing Ireland is the first facility on the island of Ireland to receive a licence from the Irish Medicines Board to manufacture culture-expanded stem cells for human use.

It is one of less than half a dozen in Europe authorised for the process.

Some 70% of pharmaceutical companies have regenerative medicine therapies in development, with 575 active trials in cell and gene therapy under way.

There are more than 1,900 cell therapy clinical trials ongoing worldwide with regenerative medicine products generating more than $1bn in revenue in 2012.

Visit link:
Stem cells lab to open in Galway

Recommendation and review posted by Bethany Smith

Embryonic stem cells have been highly valued for their ability to turn into any type of cell in the body.

Stem cells can be manufactured for human use for the first time in Ireland, following Irish Medicines Board licensing of a new facility in Galway.

NUI Galways Centre for Cell Manufacturing Ireland aims to culture adult stem cells to tackle conditions such as arthritis, heart disease, diabetes and associated conditions.

The centre, which is one of less than half a dozen in Europe authorised for stem cell manufacture, has been developed by researchers at NUIGs regenerative medicine institute.

Stem cells serve as the bodys repair mechanism. They can be isolated from tissues such as bone marrow and fat, and cultured in laboratory settings.

More controversially, embryonic stem cells have been highly valued for their ability to turn into any type of cell in the body, but scientists can now use reprogrammed adult skin cells to create a stem cell that is very similar to embryonic versions.

The centre will be opened today by Minister of State for Research and Innovation Sen Sherlock, at a time when the Health Research Board and Science Foundation Ireland have approved funding there for clinical trials on using mesenchymal stem cells cells that can differentiate into a variety of types for treatment of critical limb ischemia, a condition associated with diabetes that can result in amputation.

The new centres director Prof Tim OBrien explained that the stem cells must be grown in the laboratory to generate sufficient quantities, following their isolation from the bone marrow of adult donors, and the facility will help Ireland to develop therapies for a broad range of clinical problems which do not have effective treatments today.

It will also allow us to translate discoveries from the basic stem cell research programme led by Prof Frank Barry at the Science Foundation Ireland-funded REMEDI to the clinic, and to be competitive for grant funding under the Horizon 2020 programme of the EU, he said.

Stem cell research in Ireland is in what scientists have described as a legislative lacuna, but this relates to use of embryonic stem cells and does not in any way inhibit the use of adult stem cells, Prof OBrien explained.

Read the original:
Ireland’s first stem cell manufacturing centre approved at NUI Galway

Recommendation and review posted by Bethany Smith

Stem cells for human use are to be made in a university lab in the first medical program of its kind in Ireland.

Scientists behind the new facility at the National University of Ireland (NUI) Galway will aim to produce adult cells to combat conditions like arthritis, heart disease and diabetes.

Stem cells created at the lab will be used in clinical trials following regulatory approval - the first of which is to test their effects on critical limb ischemia, a common complication associated with diabetes which often results in amputation.

The cells, mesenchymal stem cells (MSCs), will undergo safety tests after being isolated from bone marrow from donors and grown in the laboratory to generate sufficient quantities.

The university said it will position it as a global player in regenerative medicine.

NUI Galway's Centre for Cell Manufacturing Ireland is the first facility in Ireland to receive a licence from the Irish Medicines Board to manufacture culture-expanded stem cells for human use.

And it is one of less than half a dozen in Europe authorised for the process.

'Developing Galway's role as med-tech hub of global standing, the Centre for Cell Manufacturing Ireland captures NUI Galway's commitment to bring bold ideas to life,' said NUI Galway president Dr Jim Browne.

'Innovation can bridge the gap between patient and provider and meet the needs of industry and the wider society in a balanced way.'

Stem cells are best described as serving as the body's repair mechanism and in recent years science has isolated them from tissues such as bone marrow and fat to recreate them in laboratory settings.

Go here to see the original:
Ireland uni lab in stem cells move

Recommendation and review posted by Bethany Smith

AAP Scientists in Ireland aim to produce adult cells to combat conditions like arthritis.

Stem cells for human use are to be made in a university lab in the first medical program of its kind in Ireland.

Scientists behind the new facility at the National University of Ireland (NUI) Galway will aim to produce adult cells to combat conditions like arthritis, heart disease and diabetes.

Stem cells created at the lab will be used in clinical trials following regulatory approval - the first of which is to test their effects on critical limb ischemia, a common complication associated with diabetes which often results in amputation.

The cells, mesenchymal stem cells (MSCs), will undergo safety tests after being isolated from bone marrow from donors and grown in the laboratory to generate sufficient quantities.

The university said it will position it as a global player in regenerative medicine.

NUI Galway's Centre for Cell Manufacturing Ireland is the first facility in Ireland to receive a licence from the Irish Medicines Board to manufacture culture-expanded stem cells for human use.

And it is one of less than half a dozen in Europe authorised for the process.

"Developing Galway's role as med-tech hub of global standing, the Centre for Cell Manufacturing Ireland captures NUI Galway's commitment to bring bold ideas to life," said NUI Galway president Dr Jim Browne.

"Innovation can bridge the gap between patient and provider and meet the needs of industry and the wider society in a balanced way."

Read this article:
Ireland university lab in stem cells move

Recommendation and review posted by Bethany Smith

Failure to legislate will hurt research

Tuesday, January 28, 2014

Even though stem cell manufacture has just been licensed in this country, the Governments ongoing failure to legislate in this area means pharmaceutical giants will still be wary of investing here, according to an expert in stem cell therapy.

CCMI General Manager Andrew Finnerty, CCMI Director Tim O'Brien, Minister Sean Sherlock and President of NUI Galway Dr. James Browne. Photograph by Aengus McMahon

Once the stem cells are harvested from the bone marrow of adult donors, they are grown in the Galway laboratory to generate sufficient quantities.

The first clinical trial using these stem cells is being funded by the Health Research Board and Science Foundation Ireland and will investigate the safety of using mesenchymal stem cells (MSCs) isolated from bone marrow for the treatment of critical limb ischemia, a complication associated with diabetes which can lead to limb amputation.

John ODea of the Irish Medical Devices Association (IMDA) said the centre was a key step.

I look forward to seeing its continued growth to assist in developing the skill sets and techniques that will be needed to embrace the new manufacturing opportunities that this exciting area will bring, he said.

The centre, one of a handful in Europe authorised for stem cell manufacture, has been developed by researchers at NUIGs regenerative medicine institute.

However, Dr Stephen Sullivan, chief scientific officer with the Irish Stem Cell Foundation warned all stem cell research operates at a pan-global level driven by big pharma and international equity firms and these players will only engage with researchers in countries where there is solid stem cell legislation in place. He welcomed the centre as a first step but said if Ireland is to compete at a top international standard, legislation remains necessary.

View post:
Failure to legislate ‘will hurt research’

Recommendation and review posted by Bethany Smith

Phoenix, AZ (PRWEB) January 26, 2014

In its continuing effort to fight ovarian cancer, Colleens Dream Foundation has granted over $20,000 to Cleveland Clinic to fund ovarian cancer research being conducted by Dr. Angela H. Ting, according to Colleens Dream Foundation President Billy Cundiff.

"Working with Cleveland Clinic has been an amazing experience," says Cundiff. "We are excited to support Dr. Ting's research."

Dr. Ting, who is an Assistant Staff of Cleveland Clinic Lerner Research Institute, says her "scientific passion" is the study of epigenetics.

She says one of her goals for her work is to establish an epigenetic signature for chemo-resistance in ovarian cancer.

"Epigenetics is defined as modifications of DNA or chromatin that do not directly change the DNA sequence but can significantly influence gene expression and organizations of the genome," says Dr. Ting. "An "epigenetic signature" is a unique epigenetic pattern that distinguishes drug resistant ovarian cancers from those that are responsive to treatments."

She says the Colleens Dream Foundation grant will allow her to conduct follow up research -on earlier pilot studies- addressing this topic.

Go here to learn more about "epigenetic signatures."

"Raising awareness and promoting research are truly the most essential and powerful strategies to improve the management of ovarian cancer and to reduce suffering due to the disease. I feel very honored to be part of this effort and greatly admire the thoughtful generosity of Mr.Lanning and Mr.Cundiff to show their support through the Kicking for the Dream program."

Cundiff, who is the kicker for the Cleveland Browns, says the $20,000 grant money given to the Cleveland Clinic and Dr. Ting was raised through Kicking For The Dream, and a Colleens Dream Foundation "grant match."

See more here:
Colleen’s Dream Foundation Grants Over $20,000 to Cleveland Clinic for Ovarian Cancer Research

Recommendation and review posted by Bethany Smith

AP Bio Genetic Engineering Survey
AP Bio Genetic Engineering Survey.

By: Matthew C

See more here:
AP Bio Genetic Engineering Survey - Video

Recommendation and review posted by Bethany Smith

By REBECCA GOURLEY WNPA Olympia News Service

OLYMPIA Fish farms in Washington are still not happy with an updated bill that intends to label transgenic fish.

Transgenic is a form of genetic engineering where the DNA is spliced to create more desirable traits.Although the new bill only addresses labeling and not the production of these fish, the industry opposes it.

Rep. Cary Condotta, R-East Wenatchee, originally filed House Bill 2143, which would prohibit the production of genetically modified finfish and would require them to be labeled when sent to supermarket shelves to be purchased as food by consumers.

Condotta has since filed House Bill 2630, which has similar language but one big difference: It doesnt prohibit production of transgenic fish.

Condotta said that because the production of transgenic fish is already banned in Washington's marine waters, including a ban in the bill was unnecessary. But people in Washington support the labeling of transgenic fish, he said, so its an issue that legislators should address.

The simplified bill also will be better for the state's aquaculture industry, because they should be concerned about their products getting mistaken for transgenic products, he said.

After listening to fish farmers criticize his original bill at a Jan. 17 hearing before the House Agriculture and Natural Resources committee, Condotta had said he was surprised by their opposition.

"We thought that the farmed fishermen would be on our side," he said, considering that several aquaculture companies have said they have no plans to rear transgenic fish in the future.

However, support for the bill was not coming from Troutlodge, an aquaculture company based in Bonney Lake, southeast of Tacoma.

Read more from the original source:
New GMO-labeling bill fails to appease fish farms

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

27-Jan-2014

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, January 27, 2014Drugs comprised of single strands of DNA, called aptamers, can bind to targets inside tumor cells causing cell death. But these DNA drugs cannot readily get inside tumor cells on their own. Effective delivery of DNA aptamers using a natural polysaccharide as a carrier is described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers. The article is available on the Nucleic Acid Therapeutics website.

Tatyana Zamay and coauthors, Krasnoyarsk State Medical University, Siberian Branch Russian Academy of Sciences, and Center for Reproductive Medicine (Krasnoyarsk, Russia), and University of Ottawa, Canada, combined the polysaccharide arabinogalactan, obtained from the larch tree, with a DNA drug that binds to and disrupts the activity of vimentin, a structural protein required for cell division. Vimentin is often over-produced by tumor cells compared to normal cells.

In the article "DNA-Aptamer Targeting Vimentin for Tumor Therapy in Vivo" the authors show that an aptamer targeting vimentin inhibits tumor growth more effectively when it is administered as a mixture with arabinogalactan than alone.

"This work demonstrates the advancement of aptamer therapeutic application through increased bioavailability using a nontoxic polysaccharide based therapy," says Executive Editor Graham C. Parker, PhD.

###

Nucleic Acid Therapeutics is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center, Durham, NC, and C.A. Stein, MD, PhD, City of Hope National Medical Center, Duarte, CA; and Executive Editor Graham C. Parker, PhD.

About the Journal

See original here:
A natural sugar delivers DNA aptamer drug inside tumor cells

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

27-Jan-2014

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, January 27, 2014Building on previous evidence showing that religious belief involves cognitive activity that can be mapped to specific brain regions, a new study has found that causal, directional connections between these brain networks can be linked to differences in religious thought. The article "Brain Networks Shaping Religious Belief" is published in Brain Connectivity, a bimonthly peer-reviewed journal from Mary Ann Liebert, Inc., publishers, and is available free on the Brain Connectivity website at http://www.liebertpub.com/brain.

Dimitrios Kapogiannis and colleagues from the National Institute on Aging (National Institutes of Health, Baltimore, MD) and Rehabilitation Institute of Chicago, IL, analyzed data collected from functional magnetic resonance imaging (fMRI) studies to evaluate the flow of brain activity when religious and non-religious individuals discussed their religious beliefs. The authors determined causal pathways linking brain networks related to "supernatural agents," fear regulation, imagery, and affect, all of which may be involved in cognitive processing of religious beliefs.

"When the brain contemplates a religious belief," says Dr. Kapogiannis, "it is activating three distinct networks that are trying to answer three distinct questions: 1) is there a supernatural agent involved (such as God) and, if so, what are his or her intentions; 2) is the supernatural agent to be feared; and 3) how does this belief relate to prior life experiences and to doctrines?"

"Are there brain networks uniquely devoted to religious belief? Prior research has indicated the answer is a resolute no," continues study co-author Jordan Grafman, Director, Brain Injury Research and Chief, Cognitive Neuroscience Laboratory, Rehabilitation Institute of Chicago. "But this study demonstrates that important brain networks devoted to various kinds of reasoning about others, emotional processing, knowledge representation, and memory are called into action when thinking about religious beliefs. The use of these basic networks for religious practice indicates how basic networks evolved to mediate much more complex beliefs like those contained in religious practice."

###

About the Journal

Brain Connectivity is the journal of record for researchers and clinicians interested in all aspects of brain connectivity. The Journal is under the leadership of Founding and Co-Editors-in-Chief Christopher Pawela, PhD, Assistant Professor, Medical College of Wisconsin, and Bharat Biswal, PhD, Chair of Biomedical Engineering, New Jersey Institute of Technology. It includes original peer-reviewed papers, review articles, point-counterpoint discussions on controversies in the field, and a product/technology review section. To ensure that scientific findings are rapidly disseminated, articles are published Instant Online within 72 hours of acceptance, with fully typeset, fast-track publication within 4 weeks. Tables of content and a sample issue may be viewed on the Brain Connectivity website at http://www.liebertpub.com/brain.

Go here to see the original:
Do brain connections help shape religious beliefs?

Recommendation and review posted by Bethany Smith

OLYMPIA Fish farms in Washington are still not happy with an updated bill that intends to label transgenic fish.

Transgenic is a form of genetic engineering where the DNA is spliced to create more desirable traits. Although the new bill only addresses labeling and not the production of these fish, the industry opposes it.

Rep. Cary Condotta, R-East Wenatchee, originally filed House Bill 2143, which would prohibit the production of genetically modified finfish and would require them to be labeled when sent to supermarket shelves to be purchased as food by consumers.

Condotta has since filed House Bill 2630, which has similar language but one big difference: It doesnt prohibit production of transgenic fish.

Condotta said that because the production of transgenic fish is already banned in Washington's marine waters, including a ban in the bill was unnecessary.

But people in Washington support the labeling of transgenic fish, he said, so its an issue that legislators should address.

The simplified bill also will be better for the state's aquaculture industry, because they should be concerned about their products getting mistaken for transgenic products, he said.

After listening to fish farmers criticize his original bill at a Jan. 17 hearing before the House Agriculture and Natural Resources committee, Condotta had said he was surprised by their opposition.

"We thought that the farmed fishermen would be on our side," he said, considering that several aquaculture companies have said they have no plans to rear transgenic fish in the future.

However, support for the bill was not coming from Troutlodge, an aquaculture company based in Bonney Lake, southeast of Tacoma.

Read more from the original source:
Rep. Condotta responds to concerned fisheries with revamped GMO bill

Recommendation and review posted by Bethany Smith

Savage Genetics - Massacre (Clip)
Clip of a tune i #39;ve been sat on for a wile i #39;m hoping to get a few tunes together for a free mini EP, as for when this will happen i #39;m not certain but keep a...

By: SGmusic09

Continued here:
Savage Genetics - Massacre (Clip) - Video

Recommendation and review posted by Bethany Smith

Study linking belly fat to genetics could lead to cure for obesity
A study at the University of Louisville linking belly fat to genetics could lead to a cure for obesity.

By: WLKY News Louisville

Originally posted here:
Study linking belly fat to genetics could lead to cure for obesity - Video

Recommendation and review posted by Bethany Smith

Bio 8.2 Mendelian Genetics Introduction

By: Heather Newman

Read the original:
Bio 8.2 Mendelian Genetics Introduction - Video

Recommendation and review posted by Bethany Smith

Embryonic stem cells have been highly valued for their ability to turn into any type of cell in the body.

Stem cells can be manufactured for human use for the first time in Ireland, following Irish Medicines Board licensing of a new facility in Galway.

NUI Galways Centre for Cell Manufacturing Ireland aims to culture adult stem cells to tackle conditions such as arthritis, heart disease, diabetes and associated conditions.

The centre, which is one of less than half a dozen in Europe authorised for stem cell manufacture, has been developed by researchers at NUIGs regenerative medicine institute.

Stem cells serve as the bodys repair mechanism. They can be isolated from tissues such as bone marrow and fat, and cultured in laboratory settings.

More controversially, embryonic stem cells have been highly valued for their ability to turn into any type of cell in the body, but scientists can now use reprogrammed adult skin cells to create a stem cell that is very similar to embryonic versions.

The centre will be opened today by Minister of State for Research and Innovation Sen Sherlock, at a time when the Health Research Board and Science Foundation Ireland have approved funding there for clinical trials on using mesenchymal stem cells cells that can differentiate into a variety of types for treatment of critical limb ischemia, a condition associated with diabetes that can result in amputation.

The new centres director Prof Tim OBrien explained that the stem cells must be grown in the laboratory to generate sufficient quantities, following their isolation from the bone marrow of adult donors, and the facility will help Ireland to develop therapies for a broad range of clinical problems which do not have effective treatments today.

It will also allow us to translate discoveries from the basic stem cell research programme led by Prof Frank Barry at the Science Foundation Ireland-funded REMEDI to the clinic, and to be competitive for grant funding under the Horizon 2020 programme of the EU, he said.

Stem cell research in Ireland is in what scientists have described as a legislative lacuna, but this relates to use of embryonic stem cells and does not in any way inhibit the use of adult stem cells, Prof OBrien explained.

Excerpt from:
Island’s first stem cell manufacturing centre approved at NUI Galway

Recommendation and review posted by simmons

Sarah, C-6 SCI, telling her story
Describing her experience at Project Walk Atlanta.

By: ProjectWalkAtlanta Spinal Cord Injury Recovery

Read the rest here:
Sarah, C-6 SCI, telling her story - Video

Recommendation and review posted by sam

Brandon lift walker early

By: ProjectWalkAtlanta Spinal Cord Injury Recovery

View post:
Brandon lift walker early - Video

Recommendation and review posted by sam

carol bridge 2

By: ProjectWalkAtlanta Spinal Cord Injury Recovery

View original post here:
carol bridge 2 - Video

Recommendation and review posted by sam

carol cable leg press

By: ProjectWalkAtlanta Spinal Cord Injury Recovery

Continued here:
carol cable leg press - Video

Recommendation and review posted by sam

Chris W Total Gym 12/16/2013

By: ProjectWalkAtlanta Spinal Cord Injury Recovery

Go here to see the original:
Chris W Total Gym 12/16/2013 - Video

Recommendation and review posted by sam

Jerry arm cycle

By: ProjectWalkAtlanta Spinal Cord Injury Recovery

The rest is here:
Jerry arm cycle - Video

Recommendation and review posted by sam

kamon walk 2

By: ProjectWalkAtlanta Spinal Cord Injury Recovery

See more here:
kamon walk 2 - Video

Recommendation and review posted by sam

Kim doing med ball reach outs
C-4/5 injury level.

By: ProjectWalkAtlanta Spinal Cord Injury Recovery

See original here:
Kim doing med ball reach outs - Video

Recommendation and review posted by sam

An early-phase clinical trial of an experimental vaccine that targets cancer stem cells in patients with recurrent glioblastoma multiforme, the most common and aggressive malignant brain tumor, has been launched by researchers at Cedars-Sinai's Department of Neurosurgery, Johnnie L. Cochran, Jr. Brain Tumor Center and Department of Neurology.

Like normal stem cells, cancer stem cells have the ability to self-renew and generate new cells, but instead of producing healthy cells, they create cancer cells. In theory, if the cancer stem cells can be destroyed, a tumor may not be able to sustain itself, but if the cancer originators are not removed or destroyed, a tumor will continue to return despite the use of existing cancer-killing therapies.

The Phase I study, which will enroll about 45 patients and last two years, evaluates safety and dosing of a vaccine created individually for each participant and designed to boost the immune system's natural ability to protect the body against foreign invaders called antigens. The drug targets a protein, CD133, found on cancer stem cells of some brain tumors and other cancers.

Immune system cells called dendritic cells will be derived from each patient's blood, combined with commercially prepared glioblastoma proteins and grown in the laboratory before being injected under the skin as a vaccine weekly for four weeks and then once every two months, according to Jeremy Rudnick, MD, neuro-oncologist in the Cedars-Sinai Department of Neurosurgery and Department of Neurology, the study's principal investigator.

Dendritic cells are the immune system's most powerful antigen-presenting cells -- those responsible for helping the immune system recognize invaders. By being loaded with specific protein fragments of CD133, the dendritic cells become "trained" to recognize the antigen as a target and stimulate an immune response when they come in contact.

The cancer stem cell study is the latest evolution in Cedars-Sinai's history of dendritic cell vaccine research, which was introduced experimentally in patient trials in 1998.

Cedars-Sinai's brain cancer stem cell study is open to patients whose glioblastoma multiforme has returned following surgical removal. Potential participants will be screened for eligibility requirements and undergo evaluations and medical tests at regular intervals. The vaccine and study-related tests and follow-up care will be provided at no cost to patients. For more information, call 1-800-CEDARS-1 or contact Cherry Sanchez by phone at 310-423-8100 or email cherry.sanchez@cshs.org.

Story Source:

The above story is based on materials provided by Cedars-Sinai Medical Center. Note: Materials may be edited for content and length.

See more here:
Clinical trial studies vaccine targeting cancer stem cells in brain cancers

Recommendation and review posted by Bethany Smith